Amanda J Boyle1, Junchao Tong1, Sami S Zoghbi2, Victor W Pike2, Robert B Innis2, Neil Vasdev3,4. 1. Azrieli Centre for Neuro-Radiochemistry, Brain Health Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada. 2. National Institute of Mental Health, Bethesda, Maryland; and. 3. Azrieli Centre for Neuro-Radiochemistry, Brain Health Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada neil.vasdev@utoronto.ca. 4. Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
Abstract
Cyclooxygenase-1 (COX-1), a biomarker for neuroinflammation, is implicated in the progression and prognosis of ovarian cancer (OvCa). This study considered the repurposing of 11C-labeled 1,5-bis(4-methoxyphenyl)-3-(2,2,2-trifluoroethoxy)-1H-1,2,4-triazole (11C-PS13), a COX-1 PET neuroimaging radiopharmaceutical, in OvCa xenograft mouse models. Methods: 11C-PS13 was evaluated in ICRscid mice with subcutaneous or intraperitoneal human OVCAR-3 OvCa xenografts by dynamic PET/MRI, ex vivo biodistribution, and radiometabolite analysis of plasma and tumor. Results: OVCAR-3 xenografts were well visualized with 11C-PS13 in xenograft mouse models. Time-activity curves revealed a steady accumulation of tumor radioactivity that plateaued from 40 to 60 min and was significantly reduced by pretreatment with ketoprofen (3.56 ± 0.81 and 1.30 ± 0.18 percentage injected dose/g without and with pretreatment, respectively, P = 0.01). Radiometabolite analysis showed that intact 11C-PS13 accounted for more than 80% of radioactivity in the tumor, with less than 20% in plasma, at 40 min after injection. Conclusion: 11C-PS13 shows promise for PET imaging of COX-1 in OvCa, and rapid translation for clinical cancer research should be considered.
Cyclooxygenase-1 (COX-1), a biomarker for neuroinflammation, is implicated in the progression and prognosis of ovarian cancer (OvCa). This study considered the repurposing of 11C-labeled 1,5-bis(4-methoxyphenyl)-3-(2,2,2-trifluoroethoxy)-1H-1,2,4-triazole (11C-PS13), a COX-1 PET neuroimaging radiopharmaceutical, in OvCa xenograft mouse models. Methods: 11C-PS13 was evaluated in ICRscid mice with subcutaneous or intraperitoneal human OVCAR-3 OvCa xenografts by dynamic PET/MRI, ex vivo biodistribution, and radiometabolite analysis of plasma and tumor. Results: OVCAR-3 xenografts were well visualized with 11C-PS13 in xenograft mouse models. Time-activity curves revealed a steady accumulation of tumor radioactivity that plateaued from 40 to 60 min and was significantly reduced by pretreatment with ketoprofen (3.56 ± 0.81 and 1.30 ± 0.18 percentage injected dose/g without and with pretreatment, respectively, P = 0.01). Radiometabolite analysis showed that intact 11C-PS13 accounted for more than 80% of radioactivity in the tumor, with less than 20% in plasma, at 40 min after injection. Conclusion: 11C-PS13 shows promise for PET imaging of COX-1 in OvCa, and rapid translation for clinical cancer research should be considered.
Authors: Inês F Antunes; Aren van Waarde; Rudi A J O Dierckx; Elisabeth G E de Vries; Geke A P Hospers; Erik F J de Vries Journal: J Nucl Med Date: 2016-12-01 Impact factor: 10.057
Authors: Matthew D Moran; Alan A Wilson; Charles S Elmore; Jun Parkes; Alvina Ng; Oleg Sadovski; Ariel Graff; Zafiris J Daskalakis; Sylvain Houle; Marc J Chapdelaine; Neil Vasdev Journal: Bioorg Med Chem Date: 2012-05-24 Impact factor: 3.641
Authors: Min-Jeong Kim; Jae-Hoon Lee; Fernanda Juarez Anaya; Jinsoo Hong; William Miller; Sanjay Telu; Prachi Singh; Michelle Y Cortes; Katharine Henry; George L Tye; Michael P Frankland; Jose A Montero Santamaria; Jeih-San Liow; Sami S Zoghbi; Masahiro Fujita; Victor W Pike; Robert B Innis Journal: Eur J Nucl Med Mol Imaging Date: 2020-05-12 Impact factor: 9.236
Authors: Meltem Ocak; Andrea G Gillman; Jamee Bresee; Lixin Zhang; Anda M Vlad; Cristina Müller; Roger Schibli; W Barry Edwards; Carolyn J Anderson; H Michael Gach Journal: Mol Pharm Date: 2015-01-14 Impact factor: 4.939
Authors: Md Jashim Uddin; Andrew J Wilson; Brenda C Crews; Paola Malerba; Md Imam Uddin; Philip J Kingsley; Kebreab Ghebreselasie; Cristina K Daniel; Michael L Nickels; Mohammed N Tantawy; Elma Jashim; H Charles Manning; Dineo Khabele; Lawrence J Marnett Journal: ACS Omega Date: 2019-05-24
Authors: György Trencsényi; Teréz Márián; Imre Lajtos; Zoltán Krasznai; László Balkay; Miklós Emri; Pál Mikecz; Katalin Goda; Gábor Szalóki; István Juhász; Enikő Németh; Tünde Miklovicz; Gábor Szabó; Zoárd T Krasznai Journal: Biomed Res Int Date: 2014-09-18 Impact factor: 3.411
Authors: Rohini Sharma; Pablo Oriol Valls; Marianna Inglese; Suraiya Dubash; Michelle Chen; Hani Gabra; Ana Montes; Amarnath Challapalli; Mubarik Arshad; George Tharakan; Ed Chambers; Tom Cole; Jingky P Lozano-Kuehne; Tara D Barwick; Eric O Aboagye Journal: Eur J Nucl Med Mol Imaging Date: 2019-11-21 Impact factor: 9.236
Authors: Carlotta Taddei; Cheryl L Morse; Min-Jeong Kim; Jeih-San Liow; Jose Montero Santamaria; Andrea Zhang; Lester S Manly; Paolo Zanotti-Fregonara; Robert L Gladding; Sami S Zoghbi; Robert B Innis; Victor W Pike Journal: ACS Chem Neurosci Date: 2021-01-25 Impact factor: 5.780
Authors: Nafiseh Ghazanfari; Aren van Waarde; Rudi A J O Dierckx; Janine Doorduin; Erik F J de Vries Journal: J Neurosci Res Date: 2021-08-04 Impact factor: 4.433